1 November 2022 updates as part of the Digital Transformation of Authority Required (Written) PBS listings
From 1 November 2022, the PBS listings for the medicines outlined in the table below will be updated as part of the Department of Health and Aged Care’s digital transformation of Authority Required (Written) Pharmaceutical Benefits Scheme (PBS) listings. Real time assessment of authority requests for these medicines will be available through Services Australia’s Online PBS Authorities (OPA) system, via Health Professional Online Services (HPOS).
For further information on these changes, please refer to the PBS news item published on 30 June 2022, ‘Digital Transformation of Authority Required (Written) PBS listings’.
The Department of Health and Aged Care is working to update all relevant PBS listings as quickly as possible. Further information will be published on the PBS website as groups of medicines are reviewed.
From 1 November 2022 the PBS listings for the following medicines will be updated
| Medicine name, Form, Quantity | PBS item code, Program code | Indication, Treatment phase |
|---|---|---|
| nintedanib 100 mg capsule, 60 | 11100F (GE) | Idiopathic pulmonary fibrosis, Initial treatment 1 – new patient |
| nintedanib 150 mg capsule, 60 | 11106M (GE) | Idiopathic pulmonary fibrosis, Initial treatment 1 – new patient |
| pirfenidone 267 mg capsule, 270 | 11136D (GE) | Idiopathic pulmonary fibrosis, Initial treatment 1 – new patient |
| pirfenidone 267 mg tablet, 90 | 11406H (GE) | Idiopathic pulmonary fibrosis, Initial treatment 1 – new patient |
| nintedanib 100 mg capsule, 60 | 12967L (GE) | Progressive fibrosing interstitial lung disease, Initial treatment |
| nintedanib 150 mg capsule, 60 | 12953R (GE) | Progressive fibrosing interstitial lung disease, Initial treatment |
| nintedanib 100 mg capsule, 60 | 12967L (GE) | Progressive fibrosing interstitial lung disease, Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements |
| nintedanib 150 mg capsule, 60 | 12953R (GE) | Progressive fibrosing interstitial lung disease, Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements |
| aflibercept 3.6 mg/0.09 mL injection, 0.09 mL syringe | 12153P (GE) | Diabetic macular oedema (DMO), Initial treatment |
| aflibercept 4 mg/0.1 mL injection, 0.1 mL vial | 10505X (GE) | Diabetic macular oedema (DMO), Initial treatment |
| dexamethasone 700 microgram implant, 1 | 10943Y (GE) | Diabetic macular oedema (DMO), Initial treatment |
| ranibizumab 1.65 mg/0.165 mL injection, 0.165 mL syringe | 10374B (GE) | Diabetic macular oedema (DMO), Initial treatment |
| ranibizumab 2.3 mg/0.23 mL injection, 0.23 mL vial | 10373Y (GE) | Diabetic macular oedema (DMO), Initial treatment |
| aflibercept 3.6 mg/0.09 mL injection, 0.09 mL syringe | 12132M (GE) | Branch retinal vein occlusion with macular oedema, Initial treatment |
| aflibercept 4 mg/0.1 mL injection, 0.1 mL vial | 11991D (GE) | Branch retinal vein occlusion with macular oedema, Initial treatment |
| aflibercept 3.6 mg/0.09 mL injection, 0.09 mL syringe | 12132M (GE) | Central retinal vein occlusion with macular oedema, Initial treatment |
| aflibercept 4 mg/0.1 mL injection, 0.1 mL vial | 11991D (GE) | Central retinal vein occlusion with macular oedema, Initial treatment |
| dexamethasone 700 microgram implant, 1 | 11469P (GE) | Branch retinal vein occlusion with macular oedema, Initial treatment |
| dexamethasone 700 microgram implant, 1 | 11469P (GE) | Central retinal vein occlusion with macular oedema, Initial treatment |
| ranibizumab 1.65 mg/0.165 mL injection, 0.165 mL syringe | 11975G (GE) | Branch retinal vein occlusion with macular oedema, Initial treatment |
| ranibizumab 1.65 mg/0.165 mL injection, 0.165 mL syringe | 11975G (GE) | Central retinal vein occlusion with macular oedema, Initial treatment |
| ranibizumab 2.3 mg/0.23 mL injection, 0.23 mL vial | 11981N (GE) | Branch retinal vein occlusion with macular oedema, Initial treatment |
| ranibizumab 2.3 mg/0.23 mL injection, 0.23 mL vial | 11981N (GE) | Central retinal vein occlusion with macular oedema, Initial treatment |
| aflibercept 3.6 mg/0.09 mL injection, 0.09 mL syringe | 12141B (GE) | Subfoveal choroidal neovascularisation (CNV), Initial treatment |
| aflibercept 4 mg/0.1 mL injection, 0.1 mL vial | 12131L (GE) | Subfoveal choroidal neovascularisation (CNV), Initial treatment |
| aflibercept 3.6 mg/0.09 mL injection, 0.09 mL syringe | 12152N (GE) | Subfoveal choroidal neovascularisation (CNV), Initial treatment |
| aflibercept 4 mg/0.1 mL injection, 0.1 mL vial | 2168D (GE) | Subfoveal choroidal neovascularisation (CNV), Initial treatment |
| brolucizumab 6 mg/0.05 mL intraocular injection, 0.05 mL syringe | 12667Q (GE) | Subfoveal choroidal neovascularisation (CNV), Initial treatment |
| ranibizumab 1.65 mg/0.165 mL injection, 0.165 mL syringe | 10138N (GE) | Subfoveal choroidal neovascularisation (CNV), Initial treatment |
| ranibizumab 2.3 mg/0.23 mL injection, 0.23 mL vial | 1382R (GE) | Subfoveal choroidal neovascularisation (CNV), Initial treatment |
| ranibizumab 1.65 mg/0.165 mL injection, 0.165 mL syringe | 11480F (GE) | Subfoveal choroidal neovascularisation (CNV), Initial treatment |
| ranibizumab 2.3 mg/0.23 mL injection, 0.23 mL vial | 11471R (GE) | Subfoveal choroidal neovascularisation (CNV), Initial treatment |